Benzinga's Microcap Movers for Monday July 9, 2012
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Shares of Preventia (PVTA), the Toronto-based cognitive learning and development company, rose 408% Monday on 6.6 million shares.
Preventia announced Monday a License Agreement with Private Trading Systems granting Preventia, Inc. a worldwide and exclusive license. Preventia can use, sub-license, enforce, and otherwise exploit, PTS UK‘s proprietary trading system designed to facilitate the trading of instruments, investments, securities and assets between buyers and sellers in a trading environment and all intellectual property incorporated therein and related thereto, which includes, but is not limited to, United States Patent No. 8,165,952 for “Electronic Trading System” and all improvements thereof and thereupon.
Preventia closed at $0.68 on Monday.
Shares of iGo (NASDAQ: IGOI), the Scottsdale, AZ manufacturer of accessories for mobile electronic devices, rose 16.67% Monday on more than twice average volume.
iGo announced Monday a global distribution agreement with Brightstar Corp., the world's largest specialized wireless distributor, whereby Brightstar will distribute a line of mobile accessories under iGo's Adapt Mobile brand.
The first products under the global distribution agreement will ship to Brightstar during the third quarter of 2012.
iGo closed at $0.49 on Monday.
Shares of NeoStem (NYSE: NBS), the New York City based biopharmaceutical company, rose 12.59% Monday on 2.5 times average volume.
NeoStem CEO Robin L. Smith sent a letter to shareholders Monday, updating recent developments and important near term catalysts for the second half of 2012. This includes a definitive agreement to divest the Company's 51% ownership interest in Suzhou Erye Pharmaceutical Co. Limited was signed on June 18th. This sale will bolster the Company's balance sheet, increase its cash position by $12,280,000, and allow it to hone its focus on its cell therapy business.
Also discussed was NeoStem's PreSERVE Phase 2 clinical trial. The company expects to achieve full enrollment over the next nine months or so and present top-line data by the end of 2013.
NeoStem closed at $0.64 on Monday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.